Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?
- 4 August 1999
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (15), 1281-1287
- https://doi.org/10.1093/jnci/91.15.1281
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Genetic Variation as a Guide to Drug DevelopmentScience, 1998
- Systems for Identifying New Drugs Are Often FaultyPublished by American Association for the Advancement of Science (AAAS) ,1997
- Genomic sciences and the medicine of tomorrowNature Biotechnology, 1996
- Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in EuropeEuropean Journal Of Cancer, 1995
- In vivo cultivation of tumor cells in hollow fibersLife Sciences, 1995
- Identifying small-molecule lead compounds: The screening approach to drug discoveryTrends in Biotechnology, 1995
- Pharmaceutical research in molecular oncologyCell, 1994
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In VivoJNCI Journal of the National Cancer Institute, 1993
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986